Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma

(2020) Christophe Lallemand et al.   Frontiers in Immunology

Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer

(2018) Mengjun Zhang et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer

(2018) Debra L. Richardson et al.   JAMA Oncology

Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study

(2018) Chun-Yan Lan et al.   LANCET ONCOLOGY

The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling

(2016) Sofia-Paraskevi Trachana et al.   PLoS One

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

(2015) Sandro Pignata et al.   LANCET ONCOLOGY

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches

(2014) Hyun-Jin Choi et al.   CANCER AND METASTASIS REVIEWS

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Metronomics: towards personalized chemotherapy?

(2014) Nicolas André et al.   Nature Reviews Clinical Oncology

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

(2012) L. C. Hanker et al.   ANNALS OF ONCOLOGY

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

(2011) Leslie M. Randall et al.   GYNECOLOGIC ONCOLOGY

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

(2010) L. Seymour et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Designs

(2009) L. Rubinstein et al.   CLINICAL CANCER RESEARCH

Prognostic role of Ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer

(2008) Gabriella Ferrandina et al.   GYNECOLOGIC ONCOLOGY

Angiogenesis as a strategic target for ovarian cancer therapy

(2008) Whitney A Spannuth et al.   Nature clinical practice. Oncology